Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2006 Oct 5;8(4):4.

Comparing the efficacy of medications for ADHD using meta-analysis

Stephen V Faraone  1 , Joseph Biederman, Thomas J Spencer, Megan Aleardi
Affiliations
Meta-Analysis

Comparing the efficacy of medications for ADHD using meta-analysis

Stephen V Faraone et al. MedGenMed. .

Abstract

Objective: Medications used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among drugs are hindered by the absence of direct comparative trials.

Methods: We analyzed recent published literature on the pharmacotherapy of ADHD to describe the variability of drug-placebo effect sizes. A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD youth published after 1979. Meta-analysis regression assessed the influence of medication type and study design features on medication effects.

Results: Twenty-nine trials met criteria and were included in this meta-analysis. These trials studied 15 drugs using 17 different outcome measures of hyperactive, inattentive, impulsive, or oppositional behavior. The most commonly identified treatments included both methylphenidate and amphetamine compounds. After stratifying trials on the class of drug studied (short-acting stimulant vs long-acting stimulant vs nonstimulant), we found significant drug differences for both study design variables and effect sizes. The differences among the 3 classes of drug remained significant after correcting for study design variables.

Conclusion: Uniformity appears to be lacking in how medication effectiveness is assessed and in many study design parameters. Comparing medication effect sizes from different studies will be biased without accounting for variability in study design parameters. Although these differences obscure comparisons among specific medications, they do allow for conclusions about the differential effects of broad classes of medications used to treat ADHD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Standardized mean differences and 95% confidence intervals (CIs) for long-acting stimulants stratified by design and type of score.
Figure 2
Figure 2
Standardized mean differences and 95% CIs for short-acting stimulants stratified by design and type of score.
Figure 3
Figure 3
Standardized mean differences and 95% CIs for nonstimulants stratified by design and type of score.
See this image and copyright information in PMC

References

    1. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry. 2003;2:104–113. - PMC - PubMed
    1. Volkow ND, Fowler JS, Wang G, et al. Mechanism of Action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6:S31–S44. - PubMed
    1. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121. - PMC - PubMed
    1. Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001;40:1352–1355. - PubMed
    1. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin North Am. 2000;9:77–97. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources